心血管风险富集的类风湿关节炎患者中托法替布对比肿瘤坏死因子抑制剂静脉血栓栓塞风险
ORAL Surveillance 试验的事后分析纳入年龄≥50岁且至少合并一项额外心血管危险因素的类风湿关节炎患者,比较托法替布5或10 mg每日两次与肿瘤坏死因子抑制剂(TNFi)的静脉血栓栓塞(VTE)风险。结果显示托法替布10 mg每日两次的VTE和肺栓塞(PE)累积概率高于TNFi,5 mg每日两次则未见高于TNFi;各治疗组内6个月间隔的发病率保持一致,VTE危险因素包括既往VTE、体重指数≥35 kg/m2、高龄和慢性肺病病史。
要点
- 托法替布10 mg每日两次的VTE和PE累积概率高于TNFi,5 mg每日两次未见高于TNFi。
- 各治疗组内6个月间隔的VTE发病率保持一致。
- VTE危险因素包括既往VTE、体重指数≥35 kg/m2、高龄和慢性肺病病史。
核心结论
- 托法替布10 mg每日两次和5 mg每日两次的VTE与PE发病率均高于TNFi,且随时间推移总体保持一致。
- 各治疗组间VTE危险因素与既往普通类风湿关节炎人群研究相一致。
- 这些数据强调在考虑对活动性类风湿关节炎患者启动托法替布或TNFi时评估VTE危险因素(包括年龄、体重指数和VTE病史)的重要性。
研究设计与样本
- ORAL Surveillance试验的事后分析,纳入年龄50岁及以上且至少合并一项额外心血管危险因素的类风湿关节炎患者。
- 患者接受托法替布5 mg或10 mg每日两次,或肿瘤坏死因子抑制剂(TNFi)治疗。
- 按6个月间隔估算经裁定的VTE、深静脉血栓和PE的累积概率与发病率(首次事件患者数/100患者年)。
- 采用Cox回归模型识别危险因素,并在VTE患者中探讨事件发生前的临床疾病活动指数。
主要发现
- 托法替布10 mg每日两次的VTE和PE累积概率高于TNFi,托法替布5 mg每日两次则未见高于TNFi。
- 各治疗组内6个月间隔的发病率保持一致。
- 各治疗组间VTE危险因素包括既往VTE、体重指数大于或等于35 kg/m2、高龄和慢性肺病病史。
- 事件发生时,大多数VTE患者按临床疾病活动指数判定为活动性疾病。
临床怎么用
- 作者认为,这些数据强调在考虑对活动性类风湿关节炎患者启动托法替布或TNFi时评估VTE危险因素(包括年龄、体重指数和VTE病史)的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The ORAL Surveillance trial found a dose-dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events with tofacitinib versus tumor necrosis factor inhibitors (TNFi). We aimed to assess VTE incidence over time and explore risk factors of VTE, including disease activity, in ORAL Surveillance. METHODS: Patients with rheumatoid arthritis (RA) aged 50 years or older with at least one additional cardiovascular risk factor received tofacitinib 5 or 10 mg twice daily (BID) or TNFi. Post hoc, cumulative probabilities and incidence rates (patients with first events/100 patient-years) by 6-month intervals were estimated for adjudicated VTE, deep vein thrombosis, and PE. Cox regression models identified risk factors. Clinical Disease Activity Index leading up to the event was explored in patients with VTE. RESULTS: Cumulative probabilities for VTE and PE were higher with tofacitinib 10 mg BID, but not 5 mg BID, versus TNFi. Incidence rates were consistent across 6-month intervals within treatments. Across treatments, risk factors for VTE included prior VTE, body mass index greater than or equal to 35 kg/m2, older age, and history of chronic lung disease. At the time of the event, most patients with VTE had active disease as defined by Clinical Disease Activity Index. CONCLUSION: Incidences of VTE and PE were higher with tofacitinib (10 > 5 mg BID) versus TNFi and were generally consistent over time. Across treatments, VTE risk factors were aligned with previous studies in the general RA population. These data highlight the importance of assessing VTE risk factors, including age, body mass index, and VTE history, when considering initiation of tofacitinib or TNFi in patients with active RA.
引用
- Charles-Schoeman C, Fleischmann R, Mysler E, et al. Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients. Arthritis Rheumatol. 2024. PMID: 38481002. doi:10.1002/art.42846
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。